ERBB2 and neoplasm: Among 14 patients with HER2-overexpressing tumours (breast and gastroesophageal cancer), 44% of those with HER2 3 + tumours (4 of 9 patients) achieved stable disease as the best overall response at 8 weeks, while no meaningful activity was observed in the HER2 2 + population.